RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-13.46%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$627M
AUM Growth
+$627M
(-11%)
Cap. Flow
+$21.3M
Cap. Flow
% of AUM
3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.67%
Holding
102
New
6
Increased
38
Reduced
34
Closed
9
Top Buys
| 1 |
Humana
HUM
|
$14.3M |
| 2 |
Cigna
CI
|
$14.3M |
| 3 |
Pfizer
PFE
|
$13.2M |
| 4 |
McKesson
MCK
|
$9.62M |
| 5 |
AET
Aetna Inc
AET
|
$9.52M |
Top Sells
| 1 |
Biogen
BIIB
|
$20.3M |
| 2 |
Johnson & Johnson
JNJ
|
$18.6M |
| 3 |
UnitedHealth
UNH
|
$9.74M |
| 4 |
CVS Health
CVS
|
$8.39M |
| 5 |
Merck
MRK
|
$7.9M |
Sector Composition
| 1 | Healthcare | 91.99% |
| 2 | Financials | 2.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$155B
| $18.7M | 2.98% | 135,000 +66,000 | +96% | +$9.13M |
|
|
ALXN
2
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $18M | 2.87% | 115,000 -17,800 | -13% | -$2.78M |
|
3
Medtronic
MDT
$119B
| $17.7M | 2.83% | 265,000 +110,200 | +71% | +$7.38M |
|
|
4
UnitedHealth
UNH
$281B
| $17.1M | 2.72% | 147,000 -84,000 | -36% | -$9.74M |
|
5
Eli Lilly
LLY
$657B
| $15.5M | 2.47% | 185,000 +10,000 | +6% | +$837K |
|
|
AET
6
DELISTED
Aetna Inc
AET
| $15.1M | 2.41% | 138,000 +87,000 | +171% | +$9.52M |
|
7
Elevance Health
ELV
$71.8B
| $15M | 2.39% | 107,000 +49,000 | +84% | +$6.86M |
|
8
Alkermes
ALKS
$4.78B
| $15M | 2.39% | 255,000 -94,000 | -27% | -$5.52M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $14.7M | 2.35% | 136,000 -1,000 | -0.7% | -$108K |
|
|
10
Humana
HUM
$36.5B
| $14.3M | 2.28% | +80,000 | New | +$14.3M |
|
|
11
Cigna
CI
$80.3B
| $14.3M | 2.28% | +105,900 | New | +$14.3M |
|
|
12
McKesson
MCK
$85.4B
| $14.2M | 2.27% | 77,000 +52,000 | +208% | +$9.62M |
|
13
HCA Healthcare
HCA
$94.5B
| $13.9M | 2.22% | 180,000 +111,000 | +161% | +$8.59M |
|
|
14
Pfizer
PFE
$141B
| $13.2M | 2.11% | +421,000 | New | +$13.2M |
|
|
AGN
15
DELISTED
Allergan plc
AGN
| $12.5M | 1.99% | 46,000 +4,000 | +10% | +$1.09M |
|
16
Cardinal Health
CAH
$35.5B
| $12.2M | 1.95% | 159,000 -56,000 | -26% | -$4.3M |
|
17
Becton Dickinson
BDX
$55.3B
| $12.1M | 1.92% | 91,000 +31,000 | +52% | +$4.11M |
|
18
Incyte
INCY
$16.5B
| $12M | 1.92% | 109,000 +1,498 | +1% | +$165K |
|
|
STJ
19
DELISTED
St Jude Medical
STJ
| $12M | 1.91% | 190,000 +107,000 | +129% | +$6.75M |
|
20
AbbVie
ABBV
$372B
| $11.4M | 1.82% | 210,000 -23,000 | -10% | -$1.25M |
|
21
Bristol-Myers Squibb
BMY
$96B
| $11.4M | 1.81% | 192,000 -6,000 | -3% | -$355K |
|
22
Gilead Sciences
GILD
$140B
| $11.3M | 1.8% | 115,000 -15,000 | -12% | -$1.47M |
|
23
Vertex Pharmaceuticals
VRTX
$100B
| $10.9M | 1.74% | 105,000 +50,000 | +91% | +$5.21M |
|
24
Perrigo
PRGO
$3.27B
| $10.2M | 1.63% | 65,000 +18,000 | +38% | +$2.83M |
|
25
Centene
CNC
$14.3B
| $9.49M | 1.51% | 175,000 +121,000 | +224% | +$6.56M |
|